Changing the paradigm of osteoarthritis treatment


Routine intra-articular injection procedure of a small-molecule drug into a joint cavity after traumatic injury to prevent osteoarthritis
First-mover that fulfills a major unmet medical need!


CartilaGen Wins Pappajohn Iowa Entrepreneurial Venture Competition


About CartilaGen

  •  Posttraumatic osteoarthritis (PTOA) is the number one disabling condition leading to medical discharge of wounded warriors from active duty

  • PTOA affects over six million civilians at a cost of nearly $15 billion annually to the United States

  • PTOA has devastating effects on patients and current treatment options are limited and ineffective before end-stage joint replacement 

  • Drug-eluting, bioactive hydrogel proven effective for PTOA prevention

  • Targets the earliest stage of PTOA development and treats the underlying disease mechanism in an easily performed, cost-effective manner

  • Designed for cartilage injuries and early stage osteoarthritis

  • Combined Phase I/IIa clinical trial scheduled

  • University of Iowa Hospitals and Clinics

  • Indiana University Health

  • US Department of Defense

  • METRC (Major Extremity Trauma and Rehabilitation Consortium)

  • Geneo Medicine


© 2019 by CartilaGen, Inc. | All Rights Reserved | Technologies have not yet been evaluated by the FDA, and are not available for public sale or distribution.